Lobe Sciences (XCNQ:LOBE) Debt-to-Equity : -0.30 (As of Feb. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Lobe Sciences Debt-to-Equity?

Lobe Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.37 Mil. Lobe Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.00 Mil. Lobe Sciences's Total Stockholders Equity for the quarter that ended in Feb. 2024 was C$-1.24 Mil. Lobe Sciences's debt to equity for the quarter that ended in Feb. 2024 was -0.30.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lobe Sciences's Debt-to-Equity or its related term are showing as below:

XCNQ:LOBE' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.08 Med: -0.01 Max: 0.08
Current: -0.3

During the past 13 years, the highest Debt-to-Equity Ratio of Lobe Sciences was 0.08. The lowest was -2.08. And the median was -0.01.

XCNQ:LOBE's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs XCNQ:LOBE: -0.30

Lobe Sciences Debt-to-Equity Historical Data

The historical data trend for Lobe Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences Debt-to-Equity Chart

Lobe Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Aug19

Aug20

Aug21

Aug22

Aug23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

-2.08

Lobe Sciences Quarterly Data
	Dec18	Mar19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	Aug23	Nov23	Feb24
Debt-to-Equity	Get a 7-Day Free Trial															-	-0.26	-2.08	-0.52	-0.30

Competitive Comparison of Lobe Sciences's Debt-to-Equity

For the Biotechnology subindustry, Lobe Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lobe Sciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lobe Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lobe Sciences's Debt-to-Equity falls into.

Lobe Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lobe Sciences's Debt to Equity Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.333	+	0)	/	-0.16
	=	-2.08

Lobe Sciences's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.368	+	0)	/	-1.235
	=	-0.30

Lobe Sciences (XCNQ:LOBE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Lobe Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Lobe Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Lobe Sciences (XCNQ:LOBE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (XCNQ:LOBE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

LOBEF:USA 6YX0:Germany

Address

1199 West Hastings Street, Suite 1400, Vancouver, BC, CAN, V6E 3T5

Website

https://www.lobesciences.com

Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications.

Lobe Sciences (XCNQ:LOBE) Headlines

No Headlines